Objective:To investigate the influence of HBV-DNA load on portal venous pressure and its molecular mech-anism in HBsAg positive chronic HBV liver cirrhosis.Methods:From January 2014 to April 201 5,86 cases of HBsAg positive chronic HBV liver cirrhosis were recruited and divided randomly into two groups as observation group and control.The obser-vation group accepted anti-virus treatment (Adefovir dipivoxil tablet 10 mg qd for 6 months)beside regular liver-protecting therapy.And the control group accepted regular therapy only.The HBV-DNA load by PCR,PV-CI in Colorful Doppler ultra-sound and NO,CO,ET-1 concentration in serum before and after the treatment were detected and analyzed in SPSS 1 9.0 for windows.Results:After treatment the observation group HBV-DNA load,PV-CI,NO,CO,ET-1 were significantly decreased as compared each to that before the treatment and that after treatment in control (P <0.05).Further Logistic regression analy-sis showed that lgHBV-DNA,Child classification,lgHBV-DNA were risk factors of hyperportal venous pressure.Conclusion:Anti-virus therapy in HBsAg positive chronic HBV liver cirrhosis could improve portal venous pressure,which might prevent serious related complications from further developing.%目的：：研究乙肝病毒载量对门静脉压力的影响及其可能分子机制.方法：2014年1月~2015年4月期间收集在重庆市渝北区人民医院治疗的 HBsAg 阳性的慢性乙型肝炎早、中期肝硬化患者86例,随机分为观察组与对照组2组,对照组予常规治疗,观察组予抗病毒治疗(阿德福韦酯片10 mg,1次/d,疗程6个月),比较2组治疗前后 HBV-DNA、门静脉充血指数及其可能影响因素 NO、CO、ET-1(内皮素-1)水平,并采用 Logistic 回归分析影响门静脉充血指数的影响因素.结果：观察组治疗前平均病毒载量 lgHBV-DNA(6．42±2．11),治疗后平均病毒载量 lgHBV-DNA (4．38±2．20),治疗前后相比较差异具有统计学意义(P ＜0．05)；对照组治疗前平均病毒载量 lgHBV-DNA(6．40±2．08),治疗后平均病毒载量 lgHBV-DNA(5．38±3．31),治疗前后相比较差异具有统计学意义(P ＜0．05).观察组治疗后与治疗前相比较,PV-CI、ET-1、CO、NO 降低,差异均有统计意义(均 P ＜0．05)；观察组治疗后与对照组相比较,PV-CI、ET-1、CO、NO 水平降低,差异亦均有统计学意义(均 P ＜0．05)；对照组治疗前后相比较,PV-CI、CO、NO、ET-1水平差异无统计学意义(P ＞0．05).多元 Logistic 回归分析结果显示病程、Child 分级、lgHBV-DNA 为影响门静脉压力指标 PV-CI 的危险因素.结论：抗病毒治疗能够减缓HBsAg 阳性的慢性乙型肝炎早、中期肝硬化门静脉高压,预防相关严重并发症的进展.
展开▼
